Navigation Links
Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit

SAN DIEGO, Sept. 5, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Company Chairman and CEO, Jim Joyce has accepted an invitation to present at the Exosomes and Circulating Biomarkers 2013 Summit on September 12th.  Mr. Joyce's presentation is entitled; "Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer." The presentation will highlight the clinical advancement of the Aethlon Hemopurifier® in treating hepatitis c virus (HCV) and discuss the opportunity to expand therapeutic indications to include cancer based on targeting the elimination of circulating tumor-secreted exosomes.  The conference will be held at the Town and Country Resort Hotel in San Diego, California.


Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA).  Under the IDE, Aethlon will enroll ten end stage renal disease (ESRD) patients infected with HCV as part of a feasibility study to demonstrate Hemopurifier safety.  Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and other disease conditions.

The conference abstract of the presentation follows:

Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer on 9/12/13 at 3:45pm pacific.

The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance. 

In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.

About Aethlon Medical

Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system.  At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers.  For more information, please visit

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's future clinical programs or provide market clearance of the Company's products, future human studies whether revenue or non-revenue generating from either compassionate use or non-compassionate use of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or sepsis therapies or as a standalone cancer or hepatitis C therapy or standalone sepsis therapy, the approval of the Company's technologies or products as a treatment against pandemic threats, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


James A. Joyce
Chairman and CEO
858.459.7800 x301

Jim Frakes
Chief Financial Officer
858.459.7800 x300

Marc Robins


SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors
2. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
3. Aethlon Medical (AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama
4. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
5. Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at
6. Aethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders
7. Aethlon Medical Discloses CEO Interview
8. Aethlon Medical (AEMD) Note: Extracorporeal Methods to Reduce Inflammation in Sepsis
9. Aethlon Medical To Present Today At The 15th International Conference On Dialysis
10. Aethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board
11. Aethlon Medical (AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma
Post Your Comments:
(Date:11/30/2015)... 2015 --> --> ... Market by Product (Soft Tissue, All Tissue, Dental Welding Lasers), ... and Geography - Global Forecast to 2020", published by MarketsandMarkets, ... a CAGR of 5.2% during the forecast period from 2015 ... and 62 Figures spread through 167 P ages and ...
(Date:11/30/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ), a clinical-stage ... delivery systems, announced today it has signed definitive licensing ... of Technologies Co., Ltd. ("HTIT") for exclusive rights to ... China , Hong Kong ... signed at the Israel Knesset (Parliament). ...
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... MOSI recently added two state-of-the-art augmented reality (AR) experiences from ... to their collection of interactive exhibits within the Kids In Charge! building. In collaboration ... to get closer than ever to a range of animals as they drink, sleep ...
(Date:11/30/2015)... ... 2015 , ... The world of hair transplants and restoration is filled with ... and procedures have been in use for many years and are among the most ... M.D. has utilized many of these methods over the years, he also keeps an ...
(Date:11/30/2015)... ... 30, 2015 , ... On Saturday, October 24th, 2015, at the Mill Race ... event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients and staff ... also located in Battle Creek, joined in for this campaign that sought to raise ...
(Date:11/30/2015)... ... 2015 , ... The presidential race normally deals with political issues of national ... national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? It ... anyone wants to admit when it comes to how people are viewed by others. ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to an ... Decker made a brave but slightly unusual choice to show her Instagram followers that ... pre-pregnancy form may have been pre-mature. Saying that she didn’t “want to mislead any ...
Breaking Medicine News(10 mins):